Recent Updates
Recently added Catalysts
DRTS Positive Sentiment Score: 75/100

Alpha Tau to Present at Jefferies Global Healthcare Conference

Key Takeaway: Alpha Tau Medical Ltd. announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025. The company focuses on the development of Alpha DaRT, an innovative alpha-radiation therapy for solid tumors. Investors can schedule one-on-one meetings with Levy during the event.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • CFO Raphi Levy will present at a prominent healthcare conference.
  • Alpha DaRT therapy shows promise in treating solid tumors.
  • The company is actively engaging with investors.

Full Press Release Details

JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025.
Event: Jefferies Global Healthcare Conference
Format: Presentation
Date: June 5, 2025
Time: 1:25 – 1:55PM ET
Location: New York, NY
Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule.
About Alpha Tau Medical Ltd.Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:IR@alphatau.com

Frequently Asked Questions

What is Alpha DaRT therapy?

Alpha DaRT is an innovative cancer treatment designed for solid tumors using alpha-radiation.

When will Alpha Tau present at the conference?

Alpha Tau will present at the Jefferies Global Healthcare Conference on June 5, 2025.

Who will represent Alpha Tau at the conference?

CFO Raphi Levy will represent Alpha Tau at the Jefferies Global Healthcare Conference.

How can investors meet with Alpha Tau's CFO?

Investors can schedule one-on-one meetings with CFO Raphi Levy through their Jefferies representative.

Last updated: May 28, 2025